The MHRA’s pharmaceutical export certification system now processes 100 percent of applications through its new digital platform, marking a complete transition from traditional paper-based administrative procedures. This comprehensive digitisation encompasses all UK-manufactured human medicines destined for international markets, affecting the entire pharmaceutical export sector.
The electronic system operates continuously with 24/7 availability, eliminating the time constraints associated with paper document workflows. Real-time access to certificate status enables companies to track applications efficiently and respond promptly to regulatory requirements. By achieving full digital processing, the MHRA demonstrates measurable progress in regulatory modernisation while maintaining stringent quality assurance protocols that protect public health across international pharmaceutical supply chains.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Key Finding
📰 Read the full article: UK Launches Digital Export Certificate System for Human Medicines →
